Discontinued — last reported Q3 '25
Viatris Accrued Litigation decreased by 91.8% to $45.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 91.3%, from $525.60M to $45.80M. Over 4 years (FY 2020 to FY 2024), Accrued Litigation shows an upward trend with a 6.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates higher legal risk or the recognition of new settlement obligations, which can negatively impact earnings.
Accrued litigation represents the estimated liability for legal claims and settlements that are probable and estimable....
Highly specific to the company's legal environment; peers in the pharmaceutical industry often carry similar provisions.
accrued_litigation| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $487.70M | $474.90M | $715.60M | $694.90M | $676.30M | $397.40M | $297.20M | $288.80M | $252.10M | $205.50M | $244.00M | $321.60M | $453.00M | $446.20M | $472.80M | $525.60M | $540.80M | $556.30M | $45.80M |
| QoQ Change | — | -2.6% | +50.7% | -2.9% | -2.7% | -41.2% | -25.2% | -2.8% | -12.7% | -18.5% | +18.7% | +31.8% | +40.9% | -1.5% | +6.0% | +11.2% | +2.9% | +2.9% | -91.8% |
| YoY Change | — | — | — | — | +38.7% | -16.3% | -58.5% | -58.4% | -62.7% | -48.3% | -17.9% | +11.4% | +79.7% | +117.1% | +93.8% | +63.4% | +19.4% | +24.7% | -91.3% |